Oxford Nanopore Technologies (ONT) Competitors

GBX 122.25 +1.75 (+1.45%)

As of 12:27 PM Eastern

ONT vs. ABC, GNS, OXB, ERGO, and SLN

Should you buy Oxford Nanopore Technologies stock or one of its competitors? MarketBeat compares Oxford Nanopore Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford Nanopore Technologies include Abcam (ABC), Genus (GNS), Oxford Biomedica (OXB), Ergomed (ERGO), and Silence Therapeutics (SLN). These companies are all part of the "biotechnology" industry.

How does Oxford Nanopore Technologies compare to Abcam?

Oxford Nanopore Technologies (LON:ONT) and Abcam (LON:ABC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Abcam has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	5.31	-£175.21M	-£15.10	N/A
Abcam	£350.40M	0.00	N/A	£0.06	N/A

Oxford Nanopore Technologies presently has a consensus price target of GBX 218.60, suggesting a potential upside of 78.81%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Oxford Nanopore Technologies is more favorable than Abcam.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Abcam	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Oxford Nanopore Technologies had 6 more articles in the media than Abcam. MarketBeat recorded 6 mentions for Oxford Nanopore Technologies and 0 mentions for Abcam. Oxford Nanopore Technologies' average media sentiment score of 1.24 beat Abcam's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Nanopore Technologies	Positive
Abcam	Neutral

18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. 2.3% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Abcam has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -64.85%. Abcam's return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
Abcam	N/A	N/A	N/A

Summary

Oxford Nanopore Technologies beats Abcam on 7 of the 13 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Genus?

Genus (LON:GNS) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Genus presently has a consensus price target of GBX 3,216.67, suggesting a potential upside of 38.03%. Oxford Nanopore Technologies has a consensus price target of GBX 218.60, suggesting a potential upside of 78.81%. Given Oxford Nanopore Technologies' higher probable upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Genus has a beta of 0.895, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.869, indicating that its stock price is 13% less volatile than the broader market.

Genus has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.30	£7.87M	£71.00	32.82
Oxford Nanopore Technologies	£223.90M	5.31	-£175.21M	-£15.10	N/A

Genus has a net margin of 7.07% compared to Oxford Nanopore Technologies' net margin of -64.85%. Genus' return on equity of 9.70% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

53.1% of Genus shares are owned by institutional investors. Comparatively, 18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. 0.7% of Genus shares are owned by company insiders. Comparatively, 2.3% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Genus and Genus both had 6 articles in the media. Oxford Nanopore Technologies' average media sentiment score of 1.24 beat Genus' score of 0.21 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Nanopore Technologies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genus beats Oxford Nanopore Technologies on 10 of the 15 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -64.85%. Oxford Nanopore Technologies' return on equity of -29.43% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	5.31	-£175.21M	-£15.10	N/A
Oxford Biomedica	£168.74M	4.44	-£143.51M	-£26.92	N/A

Oxford Nanopore Technologies has a beta of 0.869, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.095, indicating that its stock price is 10% more volatile than the broader market.

Oxford Nanopore Technologies currently has a consensus price target of GBX 218.60, indicating a potential upside of 78.81%. Oxford Biomedica has a consensus price target of GBX 687, indicating a potential upside of 10.99%. Given Oxford Nanopore Technologies' higher possible upside, research analysts plainly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Oxford Nanopore Technologies had 5 more articles in the media than Oxford Biomedica. MarketBeat recorded 6 mentions for Oxford Nanopore Technologies and 1 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 1.24 beat Oxford Biomedica's score of 0.67 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Nanopore Technologies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

18.9% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 2.3% of Oxford Nanopore Technologies shares are held by insiders. Comparatively, 25.9% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Oxford Nanopore Technologies and Oxford Biomedica tied by winning 8 of the 16 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Ergomed?

Oxford Nanopore Technologies (LON:ONT) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Oxford Nanopore Technologies currently has a consensus price target of GBX 218.60, suggesting a potential upside of 78.81%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Oxford Nanopore Technologies is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Oxford Nanopore Technologies has a beta of 0.869, indicating that its share price is 13% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

Ergomed has a net margin of 9.87% compared to Oxford Nanopore Technologies' net margin of -64.85%. Ergomed's return on equity of 18.08% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
Ergomed	9.87%	18.08%	10.16%

Ergomed has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	5.31	-£175.21M	-£15.10	N/A
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 2.3% of Oxford Nanopore Technologies shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Oxford Nanopore Technologies had 6 more articles in the media than Ergomed. MarketBeat recorded 6 mentions for Oxford Nanopore Technologies and 0 mentions for Ergomed. Oxford Nanopore Technologies' average media sentiment score of 1.24 beat Ergomed's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Nanopore Technologies	Positive
Ergomed	Neutral

Summary

Ergomed beats Oxford Nanopore Technologies on 8 of the 15 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

In the previous week, Oxford Nanopore Technologies had 6 more articles in the media than Silence Therapeutics. MarketBeat recorded 6 mentions for Oxford Nanopore Technologies and 0 mentions for Silence Therapeutics. Oxford Nanopore Technologies' average media sentiment score of 1.24 beat Silence Therapeutics' score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Oxford Nanopore Technologies	Positive

Oxford Nanopore Technologies has a consensus price target of GBX 218.60, suggesting a potential upside of 78.81%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Silence Therapeutics has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
Oxford Nanopore Technologies	£223.90M	5.31	-£175.21M	-£15.10	N/A

Silence Therapeutics has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -64.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

18.9% of Oxford Nanopore Technologies shares are held by institutional investors. 2.3% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Oxford Nanopore Technologies beats Silence Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Oxford Nanopore Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONT vs. The Competition

Export

Metric	Oxford Nanopore Technologies	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£1.19B	£458.97M	£6.29B	£2.79B
Dividend Yield	N/A	3.86%	2.79%	6.09%
P/E Ratio	-8.10	3.81	20.87	366.15
Price / Sales	5.31	7,812.85	521.63	88,429.84
Price / Cash	4.04	13.13	42.94	27.89
Price / Book	1.82	83.88	9.86	7.74
Net Income	-£175.21M	-£96.07M	£3.55B	£5.89B
7 Day Performance	5.94%	0.71%	-0.32%	0.82%
1 Month Performance	11.04%	0.60%	1.34%	2.78%
1 Year Performance	-8.50%	70.45%	41.03%	87.90%

Oxford Nanopore Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONT Oxford Nanopore Technologies	2.649 of 5 stars	GBX 122.25 +1.5%	GBX 218.60 +78.8%	-11.6%	£1.19B	£223.90M	N/A	1,281	News Coverage Insider Trade Gap Down
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
GNS Genus	3.5978 of 5 stars	GBX 2,269.49 -1.8%	GBX 3,216.67 +41.7%	+8.3%	£1.51B	£672M	31.96	480	News Coverage Positive News Analyst Forecast Insider Trade
OXB Oxford Biomedica	1.7203 of 5 stars	GBX 635 -1.9%	GBX 687 +8.2%	+115.8%	£767.84M	£168.74M	N/A	891	Positive News
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:ONT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Nanopore Technologies (ONT) Competitors

ONT vs. ABC, GNS, OXB, ERGO, and SLN

How does Oxford Nanopore Technologies compare to Abcam?

Summary

How does Oxford Nanopore Technologies compare to Genus?

Summary

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Summary

How does Oxford Nanopore Technologies compare to Ergomed?

Summary

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONT vs. The Competition

Oxford Nanopore Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Nanopore Technologies (ONT) Competitors

ONT vs. ABC, GNS, OXB, ERGO, and SLN

How does Oxford Nanopore Technologies compare to Abcam?

Which has better valuation & earnings, ONT or ABC?

Do analysts recommend ONT or ABC?

Does the media prefer ONT or ABC?

Do insiders and institutionals have more ownership in ONT or ABC?

Is ONT or ABC more profitable?

Summary

How does Oxford Nanopore Technologies compare to Genus?

Do analysts recommend GNS or ONT?

Which has more risk and volatility, GNS or ONT?

Which has stronger valuation and earnings, GNS or ONT?

Is GNS or ONT more profitable?

Do institutionals and insiders have more ownership in GNS or ONT?

Does the media refer more to GNS or ONT?

Summary

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Is ONT or OXB more profitable?

Which has better earnings and valuation, ONT or OXB?

Which has more volatility & risk, ONT or OXB?

Do analysts rate ONT or OXB?

Does the media prefer ONT or OXB?

Do insiders & institutionals hold more shares of ONT or OXB?

Summary

How does Oxford Nanopore Technologies compare to Ergomed?

Do analysts rate ONT or ERGO?

Which has more risk and volatility, ONT or ERGO?

Is ONT or ERGO more profitable?

Which has stronger valuation and earnings, ONT or ERGO?

Do insiders & institutionals believe in ONT or ERGO?

Does the media favor ONT or ERGO?

Summary

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Does the media refer more to SLN or ONT?

Do analysts recommend SLN or ONT?

Which has stronger earnings & valuation, SLN or ONT?

Is SLN or ONT more profitable?

Do insiders and institutionals believe in SLN or ONT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONT vs. The Competition

Oxford Nanopore Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools